Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation
David J. DeGraff(Penn State Milton S. Hershey Medical Center), Robert J. Matusik(Vanderbilt University Medical Center), Mary K. Herrick(University of Florida), Xiuping Yu(Vanderbilt University Medical Center), Michael S. Cookson(University of Oklahoma Health Sciences Center), Gary D. Steinberg(Rush University Medical Center), Xue‐Ru Wu(Chongqing Medical University), Hironobu Yamashita(Penn State Milton S. Hershey Medical Center), Shahrokh F. Shariat(Universitätszahnklinik Wien), Peter E. Clark(Levine Cancer Institute), Victoria Robinson(University of Connecticut), Sam S. Chang(Vanderbilt University), Henry F. Frierson(University of Virginia), Justin Cates(Vanderbilt University Medical Center), Mark E. Smolkin(University of Virginia), Dan Theodorescu(University of Arizona)
Cited by 111
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
|Proceedings of the National Academy of Sciences|2013|1.4k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Advances in bladder cancer biology and therapy
|Nature reviews. Cancer|2020|783